This study looks at the 16-year results of 2 clinical Purpose: To update the previous report from 2 randomized clinical trials, now with a median follow-up of 16 years, to analyze the effect of radiation therapy timing on local failure and disease-free survival.
trials that required radiation therapy after surgery and chemotherapy for patients who received breastconserving surgery. Patients received radiation therapy after initial chemotherapy within 2 months, 4 months, and 7 months after surgery. Our results confirm no increased risk of local failures in patients delaying their radiation therapy until after systemic treatment.
Patients and Methods: From July 1986 to April 1993, International Breast Cancer Study Group trial VI randomly assigned 1475 pre-/perimenopausal women with node-positive breast cancer to receive 3 or 6 cycles of initial chemotherapy (CT). International Breast Cancer Study Group trial VII randomly assigned 1212 postmenopausal women with node-positive breast cancer to receive tamoxifen for 5 years, or tamoxifen for 5 years with 3 early cycles of initial CT. For patients who received breast-conserving surgery (BCS), radiation therapy (RT) was delayed until initial CT was completed; 4 or 7 months after BCS for trial VI and 2 or 4 months for trial VII. We compared RT timing groups among 433 patients on trial VI and 285 patients on trial VII who received BCS plus RT. Endpoints were local failure, regional/distant failure, and disease-free survival (DFS). Results: Among pre-/perimenopausal patients there were no significant differences in disease-related outcomes. The 15-year DFS was 48.2% in the group allocated 3 months initial CT and 44.9% in the group allocated 6 months initial CT (hazard ratio [HR] 1.12; 95% confidence interval [CI] 0.87-1.45). Among postmenopausal patients, the 15-year DFS was 46.1% in the no-initial-CT group and 43.3% in the group allocated 3 months initial CT (HR 1.11; 95% CI 0.82-1.51). Corresponding HRs for local failures were 0.94 (95% CI 0.61-1.46) in trial VI and 1.51 (95% CI 0.77-2.97) in trial VII. For regional/distant failures, the respective HRs were 1.15 (95% CI 0.80-1.63) and 1.08 (95% CI 0.69-1.68).
Conclusions: This study confirms that, after more than 15 years of follow-up, it is reasonable to delay radiation therapy until after the completion of standard CT. Ó 2016 Elsevier Inc. All rights reserved.
Introduction
Postoperative radiation therapy to the breast after breastconserving surgery increases local control rates and longterm survival (1) . The optimal timing of this common radiation therapy is still not known. To start postoperative adjuvant treatment as soon as reasonably possible seems logical because the aim of the adjuvant treatment is to eradicate remaining clonogenic cells after surgery, and the probability of success would theoretically be better if the time for these cells to proliferate after surgery were shorter (2) . However, the risk of waiting before initiating adjuvant radiation therapy differs among cancers and cancer subtypes (3).
Several retrospective breast cancer studies on the effect of delay of radiation therapy have yielded variable results (4) (5) (6) (7) (8) . Often the time to start irradiation is not independent of the primary tumor characteristics, making interpretations difficult. Generally an increased risk for local failure with longer delay between surgery and radiation therapy was seen in univariate analysis, but this effect was not observed after adjusting for prognostic factors in multivariate analysis. In a report from the International Breast Cancer Study Group (IBCSG), no increased risk was observed with a delay of up to 20 weeks for patients with hormone receptorepositive breast cancer receiving endocrine therapy (9) .
Three review articles indicate an increased risk for local failures with a longer delay than 8 weeks between surgery and radiation therapy (3, 10, 11) . These reviews, however, include a variety of different study designs and various breast cancer subtypes.
A previous IBCSG publication reported the effect of delaying radiation therapy in patients randomized to different chemotherapy (CT) regimens (12) . In this study, no significant difference was observed in 4-year local failure rate among pre-/perimenopausal patients starting radiation therapy after 3 or 6 courses of CT or among postmenopausal patients starting radiation therapy within 3 months after surgery or after 3 courses of CT. An advantage with this study was that the delay of radiation therapy was predefined by the study protocol and independent of primary tumor characteristics. However, the median follow-up was only 4 years and the power too low to exclude clinically relevant differences in outcome.
The aims of the present study were to update the previous report (12) with a median follow-up of 16 years, to analyze the effect of radiation therapy timing on local failure rates and disease-free survival, and to further study possible modifying effects of estrogen-receptor status, nodal status, and age.
Patients and Methods
The clinical trial designs and treatment details have been previously published (12) (13) (14) . In brief, patients were recruited to IBCSG trial VI (pre-/perimenopausal) and IBCSG trial VII (postmenopausal) from July 1986 to April 1993 and were randomized to the treatment groups shown in Table 1 . A total of 2687 patients meeting eligibility criteria were enrolled in the two trials (1475 in trial VI and 1212 in trial VII). Of these, 718 (27%) elected to undergo breast-conserving surgery and radiation therapy subsequent to CT (as required by protocol in both trials). Thus, the differing CT schedules (Table 1 ) resulted in 4 radiation therapy timing groups: pre-/perimenopausal patients assigned to receive radiation therapy beginning 4 months from surgery (3 months initial CT then radiation therapy, CTÂ3/RT); pre-/perimenopausal patients assigned to receive radiation therapy beginning 7 months from surgery (6 months initial CT then radiation therapy, CTÂ6/RT); postmenopausal patients assigned to receive radiation therapy within 2 months after surgery (no initial CT, radiation therapy after surgery); and postmenopausal patients assigned to receive radiation therapy at 4 months (3 months initial CT then radiation therapy, CTÂ3/RT). The protocols were approved by the relevant ethics committees as required by the governing bodies in each country at the time.
According to the protocol, radiation therapy was to be given by 2 opposing tangential fields encompassing the entire breast parenchyma. None of the regional lymph node areas were specifically included in the target volume. However, no special attempt was made to exclude part of the internal mammary or lower axillary lymph nodes if these interfered with the irradiation of the breast. A planned dose of 50 Gy, in a specification point in the middle of the breast along the central axis of the 2 opposing tangential fields, was prescribed. The radiation therapy was given with daily 2-Gy fractions 5 times per week. A boost was not prescribed according to the protocol but was left to the discretion of each radiotherapist.
We compared outcomes and patterns of failure for the radiation therapy groups according to intention to treat. Outcomes were disease-free survival (DFS) and time to recurrence. Disease-free survival was defined as the time from randomization until the first occurrence of invasive breast cancer in any site (including ipsilateral breast, contralateral breast, regional, distant), second (non-breast) primary tumor, or death from any cause. Time to recurrence was defined as the time from randomization to diagnosis of recurrent breast cancer or, if confirmed later, when it was first suspected. Site of recurrence was defined as local, regional, or distant. Recurrence sites were considered to be simultaneous if they were diagnosed within 2 months of one another.
We also investigated the timing of RT in an as-treated analysis. This analysis provided results very similar to the intention-to-treat analysis (data not shown) and did not alter our conclusions in any way.
We analyzed DFS using the Kaplan-Meier product limit method and the log-rank test to compare the radiation therapy groups. We assessed time to recurrence according to type of recurrence using methods for competing risks analysis (15) . We used proportional-hazards regression and competing-risks regression to evaluate the impact of covariates on outcome (16) . Covariates were estrogen receptor status (defined as negative for <10 fmol/mg cytosol protein, otherwise positive), number of positive lymph nodes involved (1-3 or !4), and age (grouped as <40 vs !40 years among pre-/perimenopausal patients and <65 vs !65 years among postmenopausal patients). A 2-sided P value of <.05 was considered statistically significant. Statistical analysis was performed using SAS version 9.3 (SAS Institute, Cary, NC) and R version 3.0.0 (R Foundation, Vienna, Austria).
Results
The characteristics of the 718 patients included in this analysis have been published previously (12) . In brief, among the 433 pre-/perimenopausal patients, 213 were in the CTÂ3/RT group and 220 were in the CTÂ6/RT group; the median age was 44 years; 73% had estrogen receptore positive disease; 24% had !4 positive lymph nodes; and 96% received radiation therapy. Among the 285 postmenopausal patients, 146 were allocated no initial CT, and 139 were in the CTÂ3/RT group; the median age was 60 years; 82% had estrogen receptorepositive disease; 27% had !4 positive lymph nodes; and 95% received radiation therapy. The median follow-up for the entire cohort was 16 years (range, 0.3-21.3 years). Table 2 shows the numbers of events observed. A total of 398 patients had a DFS event.
There were a total of 114 local failures (with or without other type of failure) and 188 distant failures (with or without regional failure). Figure 1 illustrates the cumulative incidence of local failures (with or without other events). Among pre-/perimenopausal patients, the 15-year cumulative incidence was 18.8% AE 2.7% (AE standard error) in the CTÂ3/RT group and 18.5% AE 2.7% in the CTÂ6/RT group (hazard ratio [HR] 0.94; 95% confidence interval [CI] 0.61-1.46). Among postmenopausal patients, 15-year cumulative incidence was 9.0% AE 2.4% in the no-initial-CT group and 14.3% AE 3.1% in the CTÂ3/RT group (HR 1.51; 95% CI 0.77-2.97). Figure 2 illustrates the cumulative incidence of regional/distant (regional or distant or both) failures. Among pre-/perimenopausal patients, the 15-year cumulative incidence was 26.4% AE 3.1% in the CTÂ3/RT group and 29.7% AE 3.1% in the CTÂ6/RT group (HR 1.15; 95% CI 0.80-1.63). Among postmenopausal patients, 15-year cumulative incidence was 24.7% AE 3.6% in the no-initial-CT group and 27.3% AE 3.9% in the CTÂ3/RT group (HR 1.08; 95% CI 0.69-1.68). Figure 3 shows no significant differences in DFS when comparing the radiation therapy groups. Among pre-/perimenopausal patients, 15-year DFS was Abbreviation: DFS Z disease-free survival. Other abbreviations as in Table 1 . 48.2% AE 3.5% in the CTÂ3/RT group and 44.9% AE 3.5% in the CTÂ6/RT group (HR 1.12; 95% CI 0.87-1.45). Among postmenopausal patients, 15-year DFS was 46.1% AE 4.3% in the no-initial-CT group and 43.3% AE 4.4% in the CTÂ3/RT group (HR 1.11; 95% CI 0.82-1.51).
We performed multivariable analyses of DFS, local failure, and regional/distant failure (Table 3) . After adjustment for nodal status, estrogen receptor status, and age, radiation therapy timing was not significantly associated with outcome. We also evaluated interaction effects in the multivariable models. In all cases, the radiation therapy timing effect was not significantly modified by nodal status, estrogen receptor status, or age. For DFS in the pre-/perimenopausal group, the interaction P values were .32, .89, and .56 for the modifying effect of nodal status, estrogen receptor status, and age, respectively. For DFS in the postmenopausal group, the respective interaction P values were .12, .15, and .96.
Discussion
With a median follow-up of 16 years and with greater statistical power we detected no significantly increased risk of local failures in patients delaying their radiation therapy until after systemic treatment. In multivariable analysis age <40 years was significantly associated with increased risk for local recurrence and nodal status; age <40 years (premenopausal) and >65 years (postmenopausal) were significantly associated with decreased DFS. However, no modifying effect of nodal status, estrogen receptor status, or age on the risk of delaying radiation therapy in the different radiation therapy timing groups could be observed. This is in line with a randomized trial in which 244 patients were randomized between 12 weeks of CT (CAMFPdcyclophosphamide, doxorubicin, methotrexate, fluorouracil, prednisone) before or after radiation therapy (17, 18) . With a median follow-up of 135 months 11% of the patients randomized to CT first versus 10% in patients having radiation therapy first developed a local recurrence. The corresponding rates for distant failures at 10 years were 35% and 36% in the 2 treatment arms, respectively (17) . The authors concluded that the low power of the study could not exclude clinically relevant differences in outcome between the arms. In a previous update of trial VI, DFS in patients receiving 3 or 6 courses of CMF (cyclophosphamide, methotrexate, fluorouracil) were equal. Three courses were shown to be adequate for patients at least 40 years old and with estrogen-positive tumors (19) .
In the present study the possible preventive effect of longer duration of adjuvant CT on risk for local recurrence could counteract a possible increased risk of delaying the start of radiation therapy, and the nature of this study could not sort out these 2 opposing effects. On the other hand, one can hypothesize that systemic treatment might be reduced by giving radiation therapy earlier, because there was no difference at all between the 2 treatment arms regarding all endpoints (Figs. 1-3) . However, for patient care it is important to consider the sum of these effects in an unbiased way. An advantage of this trial was the independence between primary tumor characteristics and delay of starting radiation therapy. The main limitation of the present study is the relatively low total number of patients, so no firm conclusions can be drawn for different subgroups of patients. For instance, in the postmenopausal group the 15-year local failure rate was 9.0%, versus 14.3% in patients starting radiation therapy within 2 months or after 4 months from surgery (HR 1.51; 95% CI 0.77-2.97).
Nevertheless, this study further confirms that it is reasonable to delay radiation therapy until after the completion of standard CT, even if small differences in local failure rates in specific subgroups still cannot be excluded. Abbreviation: CI Z confidence interval. Other abbreviations as in Table 1 .
